EPG Online Twitter
EPG Online Blog
Disease Knowledge
Drug Updates
Indicated either alone or in combination with systemic therapy, in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcus spp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with fusidic acid applied topically include: impetigo contagiosa, superficial folliculitis, sycosis barbae, paronychia and erythrasma; also such secondary skin infections as infected eczematoid dermatitis, infected contact dermatitis and infected cuts / abrasions.
- Fostair 100/6 inhalation solution
- Epanutin capsules 25, 50 and 100mg
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- FemSeven Conti
- Epanutin 300mg hard capsules
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Phenergan Injection
- Rivotril 0.5 mg and 2 mgTablets
- Rivotril Ampoules
- RELPAX 20mg and 40mg Film-Coated Tablets
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 750 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 10mg Capsules
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- VALTREX Tablets 250mg
- Vesicare 5mg & 10mg film-coated tablets
- Zomig 5mg Nasal Spray
- Water for Injections
- Tizanidine 2mg Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 10 mg hard capsules
- Orfadin 2 mg hard capsules
- Natecal D3 Chewable Tablets
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Antibacterial agent
fusidic acid
Fucidin® Cream contains fusidic acid Ph.Eur. 2%. Excipient: butylhydroxyanisole Excipient: cetyl alcohol Excipient: potassium sorbate
Cream for topical administration
Indicated either alone or in combination with systemic therapy, in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcus spp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with fusidic acid applied topically include: impetigo contagiosa, superficial folliculitis, sycosis barbae, paronychia and erythrasma; also such secondary skin infections as infected eczematoid dermatitis, infected contact dermatitis and infected cuts / abrasions.
Adults and Children:
Uncovered lesions – a small quantity should be applied to the affected area twice daily until a satisfactory response is obtained. A single treatment course should not normally exceed 2 weeks.
Covered lesions - less frequent applications may be adequate.
Known hypersensitivity to fusidic acid/sodium fusidate or to any of the excipients
Infection caused by non-susceptible organisms, in particular, Pseudomonas aeruginosa.
Bacterial resistance has been reported to occur with the use of fusidic acid. As with all antibiotics, extended or recurrent use may increase the risk of developing antibiotic resistance.
Extended or recurrent use may increase the risk of developing contact sensitisation.
Fusidic acid does not appear to cause conjunctival irritation in experimental animals. Caution should still be exercised, however, when Fucidin Cream is used near the eyes.
Fucidin® Cream contains butylhydroxyanisole, cetyl alcohol and potassium sorbate which may cause local skin reactions (e.g. contact dermatitis). Butylhydroxyanisole may also cause irritation to the eyes and mucous membranes.
None known
Based on combined clinical data for Fucidin® cream and Fucidin® ointment, less than 5% of patients can be expected to experience an undesirable effect.
The most frequently reported adverse drug reactions are various skin reactions and in particular application site reactions.
Undesirable effects are listed by MedDRA SOC and the individual undesirable effects are listed starting with the most frequently reported.
Very common
1/10
Common
1/100 and <1/10
Uncommon
1/1,000 and <1/100
Rare
1/10,000 and <1/1,000
Very rare <1/10,000
Not known (cannot be estimated from the available data)
Immune system disorders
Rare
Hypersensitivity
Eye disorders
Rare
Conjunctivitis
Skin and subcutaneous tissue disorders
Uncommon
Pruritus
Rash including erythematous, maculo-papular and pustular reactions
Contact Dermatitis
Irritation at site of application (including pain, stinging, burning and erythema)
Not known
Urticaria
Angioedema
Eczema
Periorbital oedema
Leo Laboratories Limited
(POM)
29 March 2012
- ALPHADERM
- ALPHOSYL HC
- AUREOCORT
- BETACAP
- Betamethasone C Cream
- BETNOVATE
- BETNOVATE -N Cream
- BETNOVATE C Ointment
- BETNOVATE RD
- BETNOVATE SCALP APPLICATION
- BETTAMOUSSE
- CALMURID HC
- CANESTEN-HC
- CUTIVATE
- Daktacort Ointment
- DERMOVATE
- DIODERM
- Diprosalic Scalp Application
- Diprosone Ointment
- ECONACORT
- EFCORTELAN
- Elocon Cream
- EUMOVATE
- EURAX-HYDROCORTISONE
- FUCIBET
- Fucidin Cream
- GREGODERM
- HAELAN
- HALCIDERM
- Hc45 Hydrocortisone Cream
- Hydrocortisone and neomycin (skin)
- LOCOID C Ointment
- LOCOID Lipocream
- LOTRIDERM
- METOSYN
- MILDISON LIPOCREAM
- MODRASONE
- NERISONE
- NYSTAFORM-HC
- PROPADERM
- QUINOCORT
- STIEDEX LOTION
- STIEDEX LP
- SYNALAR
- TERRA-CORTRIL
- TRI-ADCORTYL
- TRIMOVATE
- ULTRALANUM
- VIOFORM-Hydrocortisone





